Fortis Healthcare Limited announced the outcome of its Board meeting held on February 13, 2026. Key approvals included the Unaudited Standalone and Consolidated Financial Results for the quarter and period ended December 31, 2025 (Q3 FY2026). Furthermore, the Board sanctioned the formulation of the Fortis Healthcare Limited Employee Stock Option Scheme 2026 (“ESOP 2026”) and approved a revision to the Related Party Transaction Policy.
Quarterly Financial Results Approval
The Board of Directors of Fortis Healthcare Limited, following its meeting on Friday, February 13, 2026, approved the Un-Audited Standalone and Consolidated Financial Results for the quarter and the nine months period ended December 31, 2025. The Statutory Auditors’ Limited Review Report accompanied these financial statements. The Board meeting commenced at 12:00 Hours (IST) and concluded at 18:40 Hours (IST).
New Employee Stock Option Scheme Sanctioned
The Board approved the formulation and implementation of a new employee stock option scheme, the Fortis Healthcare Limited Employee Stock Option Scheme 2026 (“ESOP 2026”), based on the recommendation of the Nomination and Remuneration Committee. This scheme is subject to shareholder approval and other necessary regulatory clearances. A pool of 1,50,99,163 (One Crore Fifty Lakh Ninety-Nine Thousand One Hundred and Sixty-Three only) employee stock options are proposed to be granted under ESOP 2026, each entitling the holder to one fully paid-up equity share of Rs. 10/- face value.
Revision to Related Party Transaction Policy
The Board also approved the Revision in Related Party Transaction Policy, with the updated policy attached to the submission. The policy review schedule is set for once every three years/Need Based, with the latest review dated February 13, 2026.
Key Financial Highlights (Standalone)
Reviewing the standalone results for the quarter ended December 31, 2025:
- Revenue from operations stood at ₹44,293 lacs, compared to ₹45,581 lacs in the previous quarter (Sep 30, 2025).
- Net Profit/(Loss) from continuing operations (after tax) was ₹2,840 lacs.
- Net profit margin for the quarter was 5.40%, an increase from 22.66% in the prior quarter.
Key Financial Highlights (Consolidated)
Consolidated figures for the quarter ended December 31, 2025:
- Total Income reached ₹227,330 lacs.
- Total Expenses were ₹196,524 lacs.
- Net Profit/(Loss) for the period (after tax) attributable to Owners of the Company was ₹19,373 lacs.
- Basic earnings per share (EPS) from continuing operations (not annualised) was 2.57 Rupees.
Segment Performance (Consolidated)
The Group continues to report two main segments: Healthcare and Diagnostics.
- Healthcare Revenue from Operations for the quarter stood at ₹193,781 lacs.
- Diagnostics Revenue from Operations for the quarter stood at ₹37,085 lacs.
- Total Segment Profit/(Loss) before interest and tax for the quarter was ₹38,550 lacs, predominantly driven by the Healthcare segment (₹33,002 lacs).
Extensive Litigation and Regulatory Matters Noted
The results documentation extensively details ongoing investigations and legal matters stemming from past transactions involving erstwhile promoters, including the SFIO investigation and legal actions related to Inter Corporate Deposits (ICDs), property advances, and brand transitions (Fortis and SRL/Agilus). The management asserts that provisions for material impacts have already been accounted for, and no further material financial impact is expected. Furthermore, details concerning the acquisition of assets from RHT Health Trust and the finalized auction and license fee payment for the ‘Fortis’ brand are provided.
Source: BSE
